医疗保险现在将涵盖林业发展局核准的多癌症血液/唾液测试,尽管在费用和准确性方面存在挑战,但批准工作仍得到加强。 Medicare will now cover FDA-approved multicancer blood/saliva tests, boosting approval efforts despite cost and accuracy challenges.

一项新的联邦支出法案授权 " 医疗保险 " 负责使用唾液或血液进行经林业发展局批准的多癌症检测测试,为公司寻求监管批准提供了重大激励。 A new federal spending bill mandates Medicare to cover FDA-approved multicancer detection tests using saliva or blood, creating a major incentive for companies to seek regulatory approval. 虽然唾液由于微生物含量和易于收集,表明有希望对癌症和病毒进行非侵入性检测,但大多数目前的检测仍然未经批准,费用高达100至200美元,没有保险,而且由于饮食、吸烟和个人生物学的自然变化,检验结果也不一致。 While saliva shows promise for non-invasive detection of cancers and viruses due to its microbial content and ease of collection, most current tests remain unapproved, costly—$100 to $200 without insurance—and inconsistent due to natural variations from diet, smoking, and individual biology. 一些牙科办公室使用家庭检测来监测感染,特别是在服务不足的地区,但广泛采用取决于克服技术、监管和负担得起的障碍。 Some dental offices use at-home tests for monitoring infections, especially in underserved areas, but widespread adoption depends on overcoming technical, regulatory, and affordability hurdles.